Aug 26 |
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
|
Aug 13 |
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
|
Aug 13 |
Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript
|
Aug 12 |
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates
|
Aug 12 |
Dare Bioscience GAAP EPS of $1.52 beats by $2.18, revenue of $22.43M
|
Aug 12 |
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
|
Aug 5 |
Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024
|
Jul 19 |
Daré Bioscience regains compliance with Nasdaq's minimum bid price rule
|
Jul 19 |
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
|
Jun 27 |
Daré Bioscience announces reverse stock split
|